EUCTR2014-001119-38-ES进行中（未招募）1 期
A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. - DTPA (BOOSTRIX)-047
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Inclusion criteria for study subjects:
- •- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •- Written informed consent obtained from the subject prior to performing any study specific procedure, as per local regulations.
- •-A healthy pregnant woman between, and including, 18 and 45 years of age at the time of screening.
- •-Pregnant subjects at 270/7-366/7 weeks (completed 27 weeks but not 37 weeks) of gestation at the time of vac-cination (Visit 1), as established by ultrasound examination.
- •-Not at high risk for complications, as determined by the obstetrical algorithm for identification of eligible subjects and the Obstetrical Risk Assessment Form.
- •-No significant foetal abnormalities, as observed by the level II ultrasound testing conducted after 18 weeks of gestation.
- •-Nuchal translucency scan, serum testing and any other prenatal tests, if conducted, should suggest normal preg-nancy.
- •-Willing to have the infant born immunised with Infanrix hexa and Prevenar 13, as per national recommendations, in the follow-up clinical studies DTPA (BOOSTRIX)-048 PRI and DTPA (BOOSTRIX)-049 BST: 048.
- •-Subjects who do not plan to give their child for adoption or place the child in care.
- •Inclusion criteria for household contacts in Spain:?Household contacts living in the same house as that of the infant.?Household contacts or parent(s)/LAR(s) of the household contacts who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. reporting of SAEs).?Written informed consent obtained from the household contacts or the parent(s)/LAR(s) prior to vaccination, as per local regulations.?Household contacts who are eligible to receive a booster dose of DTP-containing vaccine according to the Summary of Product Characteristics (SmPC) of Boostrix and according to the local governmental recommendations in Spain.?Female household contacts of non-childbearing potential may be enrolled in the study.-Non-childbearing potential is defined as premenarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.?Female household contacts of childbearing potential may be enrolled in the study , if the household contact-has practiced adequate contraception for 30 days prior to vaccination,-has a negative pregnancy test on the day of vaccination and-has agreed to continue adequate contraception for 2 months after receiving the vaccine dose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 680
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria for study subjects:?Subjects diagnosed with multiple pregnancies (twins, triplets etc.) ?Previous vaccination containing diphtheria, tetanus or pertussis antigensor diphtheria and tetanus toxoids at any time during the current pregnancy ?Women with co-morbid medical or obstetric conditions that in the opinion of the investigator have the potential to complicate the pregnancy course and outcomes ?Gestational diabetes as determined by glucose tolerance test conducted after 20 weeks of gestation, as per local recommendations of the country ?History of early onset (<34 weeks of gestation) of eclampsia/pre-eclampsia in previous pregnancy ?History of major congenital anomalies in previous pregnancies ?Use of any investigational or non-registered product other than the study vaccine anytime during the current pregnancy or planned use during the study period ? Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe ?Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the 1st vaccine. For corticosteroids, this will mean prednisone >= 20 mg/day, or equivalent. Inhaled and topical steroids are allowed ?Administration of long-acting immune-modifying drugs at any time during the study period ?Planned administration/administration of a vaccine not foreseen by the study protocol in the period within the period starting 30 days before and 30 days after the dose of vaccine with the exception of seasonal influenza vaccine that can be administered anytime during the study period ?Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product . ?Serious underlying medical condition ?History of an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine ?History of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus ?Significant mental illness ?Family history (1st degree relatives only) of congenital anomalies, recurrent pregnancylosses (2 or more consecutive losses) and unexplained neonatal death(s)in the subject ?Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination ?History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine ?History of febrile illness within the past 72 hours ?History of physician-diagnosed or laboratory-confirmed pertussis within the past 5 years ? Anything that would prevent subject from completing the study or put the subject at risk, as determined by the investigator ?Acute disease and/or fever at the time of enrolment ?Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study vaccine, or planned administration during the study period, with the exception of anti-D (Rh)-immunoglobulin ?History of chronic excessive alcohol consumption and/or drug abuse.
- •Exclusion criteria for household contacts in Spain?Child in care ?Concurrently participating in another clinical study, at any time during the study period, in which the household contact has been or will be exposed to an investigational or a non-investigational product ?Us
研究者
相似试验
进行中（未招募）
1 期
Immunogenicity and safety study of Boostrix in pregnant women.EUCTR2014-001119-38-ITGLAXOSMITHKLINE BIOLOGICALS680
进行中（未招募）
1 期
Immunogenicity and safety study of Boostrix in pregnant women.EUCTR2014-001119-38-FIGlaxoSmithKline Biologicals680
进行中（未招募）
4 期
Evaluation of safety and immunogenicity of a Human Papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected femalesCTRI/2009/091/001039GlaxoSmithKline Biologicals708
进行中（未招募）
1 期
Evaluation of safety and immunogenicity of a Human Papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females.For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and CIN 3), caused by oncogenic HPV types 16 and 18.MedDRA version: 19.0Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865MedDRA version: 19.0Level: LLTClassification code 10058580Term: Human papilloma virus serology testSystem Organ Class: 100000004848EUCTR2013-003429-28-EEGlaxoSmithKline Biologicals700
进行中（未招募）
1 期
A phase IV, randomized, double blind cross-over study to evaluate palatability of Patiromer compared to Sodium Polystyrene Sulfonate in healthy subjectsTreatment of hyperkalaemiaMedDRA version: 21.1Level: PTClassification code 10020646Term: HyperkalaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2019-004696-40-FRVifor (International) Inc.68